HCPLive 5 Stories in Under 5: Week of 06/22
カートのアイテムが多すぎます
ご購入は五十タイトルがカートに入っている場合のみです。
カートに追加できませんでした。
しばらく経ってから再度お試しください。
ウィッシュリストに追加できませんでした。
しばらく経ってから再度お試しください。
ほしい物リストの削除に失敗しました。
しばらく経ってから再度お試しください。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
HCPLive 5 Stories in Under 5: Week of 06/22
-
ナレーター：
-
著者：
このコンテンツについて
Interested in a more traditional, text rundown? Check out the HCPFive!
Top 5 Healthcare Headlines for June 16-22, 2025:
Pemvidutide Shows Significant MASH Effects, Weight Loss at 24 Weeks in Phase 2b IMPACT Trial
Topline phase 2b data show pemvidutide achieved significant rates of MASH resolution and fibrosis improvement alongside meaningful weight loss at 24 weeks, positioning it as a promising candidate for metabolic liver disease treatment.
FDA Approves Belimumab (Benlysta) Autoinjector for Pediatric Lupus Nephritis
The FDA approved a belimumab autoinjector for at-home subcutaneous use in children as young as five with active lupus nephritis, providing the first approved biologic self-injection option for pediatric SLE and LN.
Phase 3 Trial Results Announced for Sotatercept-csrk in Pulmonary Arterial Hypertension
Positive phase 3 results show sotatercept-csrk added to background therapy reduced time to clinical worsening events in adults with PAH, supporting its potential as an effective treatment for this high-risk population.
Compass Pathways’ COMP360 Psilocybin Shows Benefit in Phase 3 TRD Trial
COMP360 psilocybin demonstrated a significant reduction in depression symptom severity in treatment-resistant depression, meeting the primary endpoint in a pivotal phase 3 trial.
Once-Monthly Obesity Drug, MariTide, Achieves Weight Loss Up to 16% at 1 Year
Phase 2 data indicate once-monthly MariTide induces substantial weight loss of up to 16% over one year, with additional improvements in glycemic control, highlighting its promise for obesity and type 2 diabetes management.